

Golden Pond Healthcare, Inc.  
Form 10-Q  
August 12, 2008  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
For the quarterly period ended June 30, 2008

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 001-33798

**GOLDEN POND HEALTHCARE, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**26-0183099**  
(I.R.S. Employer  
Identification No.)

**1120 Post Road, 3rd Floor**

**Darien, CT 06820**

(Address of principal executive offices and Zip Code)

**(203) 202-3850**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject

## Edgar Filing: Golden Pond Healthcare, Inc. - Form 10-Q

to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer   
Non-accelerated filer

Accelerated filer   
Smaller reporting company

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes  No

Number of shares of Common Stock of Golden Pond Healthcare, Inc. issued and outstanding as of August 12, 2008: 21,093,750 shares of common stock, par value \$0.001 per share, of which 16,875,000 such shares are publicly traded.

**Table of Contents**

**Golden Pond Healthcare, Inc.**  
**(a corporation in the development stage)**

**Table of Contents**

**PART I FINANCIAL INFORMATION (UNAUDITED)**

		Page #
Item 1.	<u>Condensed Financial Statements:</u>	
	<u>Condensed Balance Sheets</u>	1
	<u>Condensed Statements of Operations</u>	2
	<u>Condensed Statements of Stockholders' Equity</u>	3
	<u>Condensed Statements of Cash Flows</u>	4
	<u>Notes to Condensed Financial Statements</u>	5
Item 2.	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	11
Item 3.	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	12
Item 4.	<u>Controls and Procedures</u>	13

**PART II OTHER INFORMATION**

Item 1A.	<u>Risk Factors</u>	14
Item 6.	<u>Exhibits</u>	14

**SIGNATURES**

15

**CERTIFICATIONS**

All other items called for by the instructions to Form 10-Q have been omitted because the items are not applicable or the relevant information is not material.

**Table of Contents****PART I****Item 1. Financial Statements****GOLDEN POND HEALTHCARE, INC.**

(a corporation in the development stage)

**CONDENSED BALANCE SHEETS**

	<b>June 30, 2008 (unaudited)</b>	<b>December 31, 2007</b>
<b>ASSETS</b>		
<b>Current assets</b>		
Cash and cash equivalents	\$ 9,000	\$ 397,000
Interest receivable from Trust Account	685,000	618,000
Prepaid income taxes	159,000	
Prepaid expenses	42,000	68,000
Total current assets	895,000	1,083,000
<b>Deferred acquisition costs</b>	<b>1,380,000</b>	
<b>Deferred tax asset</b>	<b>225,000</b>	<b>48,000</b>
<b>Investment in Trust Account</b> , excluding interest earned to date	<b>132,725,000</b>	<b>132,725,000</b>
	<b>\$ 135,225,000</b>	<b>\$ 133,856,000</b>
<b>LIABILITIES AND STOCKHOLDERS EQUITY</b>		
<b>Current liabilities</b>		
Accounts payable and accrued expenses	\$ 1,104,000	\$ 212,000
Income taxes payable		238,000
Notes payable, stockholder, including accrued interest		215,000
Total current liabilities	1,104,000	665,000
<b>Long-term liability</b> , deferred underwriters fee	<b>4,050,000</b>	<b>4,050,000</b>
<b>Commitments and contingencies</b>		
<b>Common stock subject to redemption</b> , 5,062,499 shares at redemption value, approximately \$7.87 per share	<b>39,817,000</b>	<b>39,817,000</b>
<b>Stockholders equity</b>		
Preferred stock, \$.001 par value; 10,000,000 shares authorized; none issued		
Common stock, \$.001 par value; 75,000,000 shares authorized; 21,093,750 shares issued and outstanding (including 5,062,499 shares subject to possible redemption)	21,000	21,000
Additional paid-in capital	89,002,000	89,002,000
Earnings accumulated during the development stage	1,231,000	301,000
Total stockholders equity	90,254,000	89,324,000
	<b>\$ 135,225,000</b>	<b>\$ 133,856,000</b>

Edgar Filing: Golden Pond Healthcare, Inc. - Form 10-Q

See accompanying notes to condensed financial statements

**Table of Contents****GOLDEN POND HEALTHCARE, INC.**

(a corporation in the development stage)

**CONDENSED STATEMENTS OF OPERATIONS**

(unaudited)

	Three months ended June 30, 2008	May 15, 2007 (date of inception) to June 30, 2007	Six months ended June 30, 2008	May 15, 2007 (date of inception) to June 30, 2008
Revenue	\$	\$	\$	\$
Formation and operating costs	181,000		456,000	580,000
Loss from operations	(181,000)		(456,000)	(580,000)
Other income (expense)				
Interest income, Trust Account	604,000		1,986,000	2,604,000
Interest income, other				2,000
Interest expense	(4,000)		(7,000)	(12,000)
Income before income tax provision	419,000		1,523,000	2,014,000
Income tax provision	157,000		593,000	783,000
Net income applicable to common stockholders	\$ 262,000	\$	\$ 930,000	\$ 1,231,000
Maximum number of shares subject to possible conversion:				
Weighted average number of common shares basic and diluted	5,062,499		5,062,499	2,463,831
Net income per common share subject to possible conversion, basic and diluted	\$		\$	\$
Weighted average number of common shares outstanding:				
Basic	21,094,000		21,094,000	13,765,000
Diluted	25,032,000		24,812,000	15,563,000
Net income per common share, basic and diluted	\$ 0.01		\$ 0.04	\$ 0.09

See accompanying notes to condensed financial statements

**Table of Contents****GOLDEN POND HEALTHCARE, INC.**

(a corporation in the development stage)

**CONDENSED STATEMENTS OF STOCKHOLDERS EQUITY**

For the period May 15, 2007 (date of inception) to June 30, 2008

	Common Stock		Additional Paid in Capital	Earnings Accumulated During Development Stage	Total Stockholders Equity
	Shares	Amount			
Sale of 4,492,188 shares of Common Stock on July 15, 2007 to Founders at \$0.001 per share	4,492,188	\$ 4,000	\$	\$	\$ 4,000
Sale of 16,875,000 units on November 13, 2007 at a price of \$8 per unit in the public offering (each unit consists of one share of common stock and one warrant to purchase a share of common stock) (including 5,062,499 shares subject to possible redemption)	16,875,000	17,000	134,983,000		135,000,000
Underwriters' discount and offering costs related to the public offering and over-allotment option (includes \$4,050,000 payable upon a business combination)			(10,164,000)		(10,164,000)
Sale of 4,000,000 warrants at \$1 per warrant on November 13, 2007 to Pecksland Partners, LLC			4,000,000		4,000,000
Common stock sold in the public offering subject to redemption (5,062,499 shares at redemption value)			(39,817,000)		(39,817,000)
Repurchase 273,438 shares from Founders at \$0.001 pursuant to redemption agreement	(273,438)				
Net income				301,000	301,000
Balances, at December 31, 2007	21,093,750	21,000	89,002,000	301,000	89,324,000
Net income				930,000	930,000
Balances, at June 30, 2008 (unaudited)	21,093,750	\$ 21,000	\$ 89,002,000	\$ 1,231,000	\$ 90,254,000

See accompanying notes to condensed financial statements

**Table of Contents****GOLDEN POND HEALTHCARE, INC.**

(a corporation in the development stage)

**CONDENSED STATEMENTS OF CASH FLOWS**

(unaudited)

	Six months ended June 30, 2008	May 15, 2007 (date of inception) to June 30, 2008
<b>Cash flows from operating activities</b>		
Net income	\$ 930,000	\$ 1,231,000
Adjustments to reconcile net income to net cash provided by operating activities:		
Deferred tax benefit	(177,000)	(225,000)
Increase (decrease) in cash attributable to changes in operating assets and liabilities		
Interest income receivable from Trust Account	(67,000)	(685,000)
Prepaid expenses	26,000	(42,000)
Accounts payable and accrued expenses and other	(212,000)	5,000
Income taxes payable/prepaid	(397,000)	(159,000)
<b>Net cash provided by operating activities</b>	103,000	125,000
<b>Cash flows from investing activities</b>		
Cash paid for deferred acquisition costs	(281,000)	(281,000)
Investment in Trust Account		(132,725,000)
<b>Net cash used in investing activities</b>	(281,000)	(133,006,000)
<b>Cash flows from financing activities</b>		
Proceeds from issuance of common stock to Founders		4,000
Proceeds from notes payable, stockholder	245,000	455,000
Repayment of notes payable, stockholder	(455,000)	(455,000)
Proceeds from the initial public offering		135,000,000
Proceeds from the issuance of warrants in private placement		4,000,000
Payments of underwriters' discount and offering costs		(6,114,000)
<b>Net cash used in provided by financing activities</b>	(210,000)	132,890,000
<b>Net increase (decrease) in cash</b>	(388,000)	9,000
<b>Cash and cash equivalents, beginning of period</b>	397,000	
<b>Cash and cash equivalents, end of period</b>	\$ 9,000	\$ 9,000
<b>Supplemental disclosure of cash flow information, cash paid during the period for income taxes</b>		
Cash paid for income taxes	\$ 1,167,000	\$ 1,167,000
<b>Supplemental disclosure of non-cash investing and financing activities</b>		
Deferred underwriters' fees	\$	\$ 4,050,000
Deferred acquisition costs accrued	\$ 1,099,000	\$ 1,099,000



Edgar Filing: Golden Pond Healthcare, Inc. - Form 10-Q

See accompanying notes to condensed financial statements

---

**Table of Contents**

**GOLDEN POND HEALTHCARE, INC.**

(a corporation in the development stage)

**Notes to Condensed Financial Statements**

**NOTE A BASIS OF PRESENTATION, DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS**

The accompanying condensed financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America. All adjustments which are of a normal recurring nature and, in the opinion of management, necessary for a fair presentation have been included. These statements should be read in conjunction with the more complete information and financial statements and notes thereto included in the Company's Annual Report on Form 10-K. Certain reclassifications have been made to the December 31, 2007 amounts to conform to the current presentation. All amounts in the accompanying condensed financial statements, except shares and per share amounts, are rounded to the nearest thousand dollars.

Golden Pond Healthcare, Inc. (a corporation in the development stage) (the Company) was incorporated in Delaware on May 15, 2007. The Company was formed to acquire, through a merger, asset acquisition, stock exchange or other similar business combination, or control through contractual arrangements, an operating business (the Business Combination). The Company is considered to be in the development stage as defined in Statement of Financial Accounting Standards (SFAS) No. 7, Accounting and Reporting By Development Stage Enterprises, and is subject to the risks associated with activities of development stage companies.

At June 30, 2008, the Company had not commenced any operations or generated operating revenues. All activity from inception through June 30, 2008 relates to the Company's formation, capital raising and the initial public offering described below. Following the offering, the Company has not and will not generate any operating revenues until after completion of its initial business combination, at the earliest. The Company generates non-operating income in the form of interest income on cash and cash equivalents (held in escrow) from the proceeds derived from the offering.

The registration statement for the Company's initial public offering (the Offering) was declared effective on November 6, 2007 and the Offering was consummated on November 13, 2007, as discussed in Note F. Preceding the consummation of the Offering, an affiliate of the Company's officers purchased 4,000,000 warrants at \$1 per warrant in a private placement (the Private Placement) that is discussed further in Note G.

The Company's management has broad discretion with respect to the specific application of the net proceeds of the Offering, although substantially all of the net proceeds of the Offering are intended to be generally applied toward consummating a business combination with (or acquisition of) a Target Business (Business Combination). As used herein, Target Business shall mean one or more businesses that at the time of the Company's initial Business Combination has a fair market value of at least 80% of the Company's net assets (all of the Company's assets, including the funds then held in the Trust Account, less the Company's liabilities (excluding deferred underwriting discounts and commissions of approximately \$4,050,000, described below). Furthermore, there is no assurance that the Company will be able to successfully effect a Business Combination.

The Company's efforts in identifying a prospective Target Business will not be limited to particular companies; however it expects to focus on operating businesses in the healthcare industry.

Since the closing of the Offering, an amount equal to approximately 98.3% of the gross proceeds has been held in a trust account (Trust Account). The Trust Account is invested in U.S. government securities, defined as any Treasury Bill issued by the United States government having a maturity of one hundred and eighty (180) days or less or money market funds meeting the conditions specified in Rule 2a-7 under the Investment Company Act of 1940, until the earlier of (i) the consummation of its first Business Combination or (ii) the distribution of the Trust Account as described below. The proceeds in the Trust Account includes \$4,050,000 of the gross proceeds representing deferred underwriting discounts and commissions that will be released to the underwriters on completion of a Business Combination. The remaining proceeds outside the Trust Account are used to pay for

**Table of Contents**

business, legal and accounting due diligence on prospective acquisitions and continuing general and administrative expenses.

The Company, after signing a definitive agreement for the acquisition of a Target Business, will submit such transaction for stockholder approval. In the event that 30% or more of the outstanding stock (excluding, for this purpose, those shares of common stock issued prior to the Offering) vote against the Business Combination, the Business Combination will not be consummated. If a majority of the shares of common stock voted by the Public Stockholders are not voted in favor of a proposed initial Business Combination but 24 months has not yet passed since closing of the Offering the Company may combine with another Target Business meeting the fair market value criterion described above.

Public Stockholders is defined as the holders of common stock sold as part of the Units in the Offering or in the aftermarket. In the event that Initial Stockholders purchase any additional Units or shares of the Company's common stock in the after market following the Proposed Offering, the Company anticipates that they will vote any shares of common stock so acquired in favor of a Business Combination.

Public Stockholders voting against a Business Combination will be entitled to convert their stock into a pro rata share of the total amount on deposit in the trust account, before payment of underwriting discounts and commissions and including any interest earned on their portion of the Trust Account net of income taxes payable thereon, and net of any interest income of up to \$2,125,000 on the balance of the Trust Account previously released to the Company, if a Business Combination is approved and completed.

In the event that the Company does not consummate a Business Combination by November 6, 2009, its corporate existence will cease except for the purposes of winding up its affairs and it will liquidate. In the event of liquidation, it is likely that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be less than the initial public offering price per share in the Offering (assuming no value is attributed to the Warrants contained in the Units sold in the Offering discussed in Note F).

**NOTE B INVESTMENT IN TRUST ACCOUNT; MARKETABLE SECURITIES**

Investment securities in the Company's Trust Account consist of (a) United States Treasury securities and (b) a mutual fund that invests in United States Treasury securities. The Company classifies its United States Treasury securities as held-to-maturity in accordance with SFAS No. 115,

Accounting for Certain Debt and Equity Securities. Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities are recorded at amortized cost and adjusted for the amortization or accretion of premiums or discounts. The Company's investment in the United States Treasury mutual fund account (approximately \$37,000 at June 30, 2008) is recorded at cost and adjusted for income distributions which occur monthly.

The carrying amount, including accrued interest, gross unrealized holding gains, and fair value of held-to-maturity securities at June 30, 2008 were as follows:

	Carrying amount	Gross unrealized holding gains	Fair value
Held-to-maturity:			
U. S. Treasury securities	\$ 133,373,000	\$ 6,000	\$ 133,379,000

At June 30, 2008, approximately \$685,000 of the trust assets, representing interest income which is available to the Company for working capital purposes, is reflected as interest receivable from trust account in the accompanying condensed financial statements. During the six months ended June 30, 2008, and for the period from May 15, 2007 (date of inception) to June 30, 2008, the Company transferred approximately \$1,916,000 from the Trust Account including approximately \$1,167,000 for payment of income taxes and approximately \$749,000 for use in working capital.

**Table of Contents****NOTE C FAIR VALUE MEASUREMENTS**

In September 2006, the Financial Accounting Standards Board ( FASB ) issued SFAS No. 157, Fair Value Measurements . The objective of SFAS 157 is to increase consistency and comparability in fair value measurements and to expand disclosures about fair value measurements. SFAS 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. SFAS 157 applies under other accounting pronouncements that require or permit fair value measurements and does not require any new fair value measurements. The provisions of SFAS No. 157 are effective for fair value measurements made in fiscal years beginning after November 15, 2007.

Effective January 1, 2008, the Company implemented SFAS No. 157, *Fair Value Measurement*, or SFAS 157, for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In accordance with the provisions of FSP No. FAS 157-2, *Effective Date of FASB Statement No. 157*, the Company has elected to defer implementation of SFAS 157 as it relates to its non-financial assets and non-financial liabilities that are recognized and disclosed at fair value in the financial statements on a nonrecurring basis until January 1, 2009. The Company is evaluating the impact, if any, this standard will have on its non-financial assets and liabilities.

The adoption of SFAS 157 did not have an impact on the Company's financial results for the periods presented in the accompanying financial statements.

The following table presents information about the Company's assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2008, and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and includes situations where there is little, if any, market activity for the asset or liability (in millions):

Description	June 30, 2008	Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
<b>Assets:</b>				
Cash and cash equivalents	\$ 9,000	\$ 9,000	\$	\$
Investment in Trust Account (including interest receivable from Trust Account of \$685,000)	133,410,000	132,416,000		
Total	\$ 133,419,000	\$ 133,425,000	\$	\$

The fair values of the Company's cash equivalents and cash and cash equivalents held in the Trust Account are determined through market, observable and corroborated sources.

The carrying amounts reflected in the balance sheets for other current assets and accrued expenses approximate fair value due to their short-term maturities.

**NOTE D DEFERRED ACQUISITION COSTS**

Deferred acquisition costs are comprised of approximately \$1,380,000 of legal, accounting, regulatory, market study and other costs associated with the Company's investigation of a potential acquisition candidate. In accordance with SFAS No. 141, *Business Combinations*, these costs are capitalized until either the completion or abandonment of the potential acquisition. If the potential acquisition is completed, these costs would be accounted for as part of the purchase price and if the potential acquisition is abandoned, these costs will be charged to expense. To date, no definitive agreements have been reached with any potential target for a business combination, however, discussions are ongoing. At June 30, 2008, approximately \$1,099,000 is included in accounts payable and accrued expenses.



## **Table of Contents**

### **NOTE E INCOME PER SHARE OF COMMON STOCK**

The Company complies with accounting and disclosure requirements of SFAS No. 128, Earnings Per Share. Basic net income per common share is computed by dividing net income applicable to common stock by the weighted average number of common shares outstanding for the period. Income per share of common stock, assuming dilution, reflects the maximum potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock and would then share in the net income of the Company, except where the results would be antidilutive. At June 30, 2008, the Company had warrants outstanding to purchase 20,875,000 shares of common stock.

The Company uses the treasury Stock Method to calculate potentially dilutive shares, as if they were converted into common stock at the beginning of the period. As of June 30, 2008, dilutive securities include 3,492,000 warrants that represent incremental common shares, based on their assumed conversion, to be included in the weighted average number of common shares for the calculation of diluted income per common share.

The Company's statement of operations includes a presentation of income per share for common stock subject to possible conversion in a manner similar to the two-class method of income per share. Net income per common share, basic and diluted amount for the maximum number of shares subject to possible conversion is calculated by dividing the interest income, net of applicable income taxes, attributable to common shares subject to conversion (\$-0- for the three and six months ended June 30, 2008 and for the period from May 15, 2007 (date of inception) to June 30, 2008) by the weighted average number of common shares subject to possible conversion.

### **NOTE F PUBLIC OFFERING**

On November 13, 2007, the Company consummated the sale of 16,875,000 units ( Units ), including 1,250,000 Units exercised pursuant to an underwriters overallotment option, at a price of \$8.00 per Unit. Each Unit consists of one share of the Company's common stock, \$0.001 par value, and one redeemable common stock purchase warrant ( Warrants ). Each Warrant entitles the holder to purchase from the Company one share of common stock at an exercise price of \$6.00 commencing on the later of (i) November 6, 2008 or (ii) the completion of a Business Combination with a target business, and will expire November 6, 2011. The Warrants are redeemable at a price of \$0.01 per Warrant upon 30 days prior notice after the Warrants become exercisable, only in the event that the last sale price of the common stock is at least \$11.50 per share for any 20 trading days within a 30 trading day period ending on the third business day prior to the date on which notice of redemption is given. If the Company is unable to deliver registered shares of common stock to the holder upon exercise of warrants during the exercise period, there will be no cash settlement of the warrants and the warrants will expire worthless.

The Company paid an underwriting discount of 4% (\$5,400,000) of the gross offering proceeds (including the over-allotment option exercise) to the underwriters at the closing of the Offering, with an additional fee of 3% (\$4,050,000) of the gross offering proceeds payable upon the Company's consummation of a Business Combination. The underwriters are not entitled to any interest accrued on the deferred discount.

### **NOTE G RELATED PARTY TRANSACTIONS**

During March 2008, the Company issued an aggregate \$245,000 unsecured 4.25% promissory notes to a principal stockholder and affiliate of the Company's officer, Pecksland Partners, LLC ( Pecksland ). On July 16, 2007, the Company issued a \$210,000 unsecured 5% promissory note to Pecksland. Both of these notes were repaid, together with accrued interest of approximately \$12,000, in June 2008.

On July 16, 2007, the Company issued 4,492,188 shares of common stock ( Initial Shares ) to the Initial Stockholders of the Company for proceeds of \$4,492. On December 17, 2007, the Company repurchased 273,438 of such Initial Shares for \$273.44 pursuant to a redemption right related to the unexercised portion of the underwriters' overallotment option (1,093,750 unexercised Units). Such redemption right is now expired. After this redemption, there are 4,218,750 Initial Shares outstanding at December 31, 2007. The Initial Stockholders have agreed that the shares they owned prior to the Offering will not be transferable until one year from the date of the closing of the initial Business Combination and will be held in an escrow account maintained by Continental Stock Transfer & Trust Company.

**Table of Contents**

The holders of a majority of the Initial Shares are entitled to make up to two demands that the Company register the resale of their shares and warrants and shares underlying the warrants. The holders of the majority of these shares may elect to exercise these registration rights at any time after completion of our initial Business Combination, subject to the transfer restrictions imposed by the lock-up agreements. In addition, these stockholders have certain piggy-back registration rights on registration statements filed subsequent to the completion of the Business Combination, subject to the transfer restrictions imposed by the lock-up agreements. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

On November 13, 2007, Pecksland Partners, LLC, purchased, in a Private Placement, 4,000,000 warrants at \$1.00 per warrant ( the Insider Warrants ). The aggregate proceeds of the Private Placement are being held in the Trust Account described in Note A. The Insider Warrants are identical to the Warrants underlying the Units of the Proposed Offering except that if they are not subject to redemption, the Insider Warrants may be exercised on a cashless basis, and cannot be sold or transferred until 90 days subsequent to the Company's completion of a Business Combination. If the Company does not complete a Business Combination, then the \$4 million proceeds will be part of the liquidating distribution to the Public Stockholders and the warrants issued under this transaction will expire worthless.

**NOTE H INCOME TAXES**

The Company recorded a deferred income tax asset of approximately \$321,000 for the tax effect of temporary differences, formation and operating costs, aggregating approximately \$580,000 at June 30, 2008.

The current and deferred components of taxes are comprised of the following for the three and six months ended June 30, 2008 and for period from May 15, 2007 (date of inception) to June 30, 2008:

	Three months ended June 30, 2008	Six months ended June 30, 2008	May 15, 2007 (date of inception) to June 30, 2008
<b>Current tax provision</b>			
Federal	\$ 286,000	\$ 710,000	\$ 900,000
State	69,000	170,000	218,000
<b>Total current tax provision</b>	<b>\$ 355,000</b>	<b>880,000</b>	<b>\$ 1,118,000</b>
<b>Deferred tax provision (benefit)</b>			
Federal	(\$148,000)	(\$220,000)	(\$259,000)
State	(36,000)	(53,000)	(62,000)
<b>Total deferred tax benefit</b>	<b>(\$184,000)</b>	<b>(\$273,000)</b>	<b>(\$321,000)</b>
<b>Provision for income taxes</b>	<b>\$ 171,000</b>	<b>\$ 607,000</b>	<b>\$ 797,000</b>

The Company has not yet begun its trade or business for U. S. tax reporting purposes. Accordingly, it could not yet recognize losses for start-up expenditures. As a result, a deferred tax asset was established for these start-up expenditures. The difference between the federal statutory rate and the effective tax rate relates to state income taxes net of federal benefit and exemptions from federal surtax levels.

The Company adopted the provisions of FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes, an Interpretation of FASB Statement No. 109 ( FIN 48 ). FIN 48 provides recognition criteria and a related measurement model for tax positions taken by companies. In accordance with FIN 48, a tax position is a position in a previously filed tax return or a position expected to be taken in a future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions shall be recognized only when it is more likely than not (likelihood of greater than 50%), based on technical merits, that the position will be sustained upon examination.

---

**Table of Contents**

Tax positions that meet the more likely than not threshold should be measured using a probability weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. The Company adopted FIN 48, which had no effect on the Company's financial positions and results of operations at this time given its limited operations and activities.

**NOTE I REDEEMABLE COMMON STOCK**

The Company's common stock that is redeemable for cash or other assets is classified outside of permanent equity because they are redeemable at the option of the holder. As discussed in Note A, the Business Combination will only be consummated if Public Shareholders holding 5,062,500 (30% of the common shares in the Offering) or more common shares do not vote against a Business Combination. As further discussed in Note A, if a Business Combination is not consummated by November 6, 2009, the Company will liquidate. Accordingly, 5,062,499 shares have been classified outside of permanent equity at redemption value. The Company recognizes changes in the redemption value immediately as they occur and adjusts the carrying value of the redeemable common stock to equal its redemption value at the end of each reporting period.

If the Company's initial Business Combination is approved, Public Stockholders voting against the Business Combination will be entitled to convert their shares of common stock into a pro rata share of the aggregate amount then on deposit in the Trust Account, including their pro rata portion of the deferred underwriting discount and any interest income earned on the trust account, net of (1) income taxes payable on the interest income on the trust account and (2) up to \$2,125,000 of interest earned on the Trust Account balance which will be available to us, net of income taxes payable, to fund working capital requirements. The per share conversion price was approximately \$7.87 at June 30, 2008.

**NOTE J NEW ACCOUNTING PRONOUNCEMENT**

The FASB issued SFAS No. 141R (revised 2007), Business Combinations, which significantly changes the financial accounting and reporting for business combination transactions. SFAS No. 141R requires the acquiring entity in a business combination to recognize all (and only) the assets acquired and liabilities assumed in the transaction and establishes the acquisition date fair value as the measurement objective for all assets acquired and liabilities assumed in a business combination. Certain provisions of this standard will, among other things, impact the determination of acquisition-date fair value of consideration paid in a business combination (including contingent consideration); exclude transaction costs from acquisition accounting; and change accounting practices for acquired contingencies, acquisition-related restructuring costs, in-process research and development, indemnification assets, and tax benefits. For the Company, SFAS No. 141R is effective for business combinations occurring after December 31, 2008. The Company is currently evaluating the future impacts and disclosures of this standard.

In December 2007, the FASB issued SFAS 160, Noncontrolling Interests in Consolidated Financial Statements – an amendment of ARB No. 51. SFAS 160 requires that ownership interests in subsidiaries held by parties other than the parent, and the amount of consolidated net income, be clearly identified, labeled and presented in the consolidated financial statements. It also requires once a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary be initially measured at fair value. Sufficient disclosures are required to clearly identify and distinguish between the interests of the parent and the interests of the noncontrolling owners. It is effective for fiscal years beginning after December 15, 2008, and requires retroactive adoption of the presentation and disclosure requirements for existing minority interests. All other requirements are applied prospectively. The Company cannot determine whether SFAS 160 will have any impact until it completes its first business combination.

Management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.



---

## **Table of Contents**

### **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations** **Special Note Regarding Forward-Looking Statements**

*This Quarterly Report on Form 10-Q (the "Report") includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as may, should, could, would, expect, plan, anticipate, believe, estimate, continue, or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other Securities and Exchange Commission filings. The following discussion should be read in conjunction with our unaudited Financial Statements and related Notes thereto included elsewhere in this Report.*

#### **Overview**

The following Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to help the reader understand the Company's financial condition and results of operations. MD&A is provided as a supplement to, and should be read in conjunction with, our financial statements and the accompanying notes thereto.

We were formed on May 15, 2007, for the purpose of effecting a merger, capital stock exchange, asset or stock acquisition or other similar business combination with one or more domestic or international operating businesses. On November 6, 2007, our Registration Statement on Form S-1 relating to our initial public offering of our units was declared effective by the Securities and Exchange Commission ("SEC") and on November 13, 2007, we consummated our initial public offering and a private placement of 4,000,000 warrants to Pecksland Partners, LLC, one of our stockholders and an affiliate of our officers and/or directors. We intend to utilize cash derived from the proceeds of our initial public offering and the private placement we consummated in connection therewith, as well as a possible issuance of our capital stock or debt, or a combination of cash, capital stock and/or debt, in effecting a business combination.

Since our IPO, we have been actively engaged in seeking a suitable business combination candidate.

#### **Results of Operations and Known Trends or Future Events**

Except for the consummation of our initial public offering and our private placement, we have neither engaged in any operations nor generated any revenues to date. For the period from May 15, 2007 (the date of our inception) to June 30, 2008, our only activities have been organizational activities and those necessary to prepare for our offering, and following our public offering, certain activities related to pursuing a target business. Those activities have included multiple proposed business combination transactions, some of which we continue to actively pursue and others which we are no longer pursuing. We will not generate any operating income until the completion of a business combination (as defined in our prospectus), should it occur. We have generated non-operating income in the form of interest income on the cash held in our trust account. We believe that the funds available to us outside of the trust account, together with the balance of the interest income (net of taxes) on the trust account releasable to us to fund our working capital requirements, will be sufficient to allow us to operate until November 6, 2009, assuming that a business combination is not consummated during that time. However, if the funds available to us are not sufficient to fund our working capital needs throughout this period, we will seek to secure additional capital to pay for, or defer payment, of all or a significant portion of any expenses we incur through November 6, 2009.

For the three months ended June 30, 2008, we had a net income of approximately \$262,000, which consisted of net interest income of approximately \$600,000 reduced by approximately \$181,000 of formation and operating costs and approximately \$157,000 of income taxes provided. Net income was affected by the

---

## **Table of Contents**

substantially lower interest rates currently available on U.S. Treasury Bills compared to rates available when we began investing late in 2007 and at the beginning of 2008. For the six months ended June 30, 2008, we had a net income of approximately \$930,000, which consisted of net interest income of approximately \$1,979,000 reduced by approximately \$456,000 of formation and operating costs and approximately \$593,000 of income taxes provided. For the period from May 15, 2007 (the date of our inception) to June 30, 2008, we had net income of approximately \$1,231,000, which consisted of net interest income of approximately \$2,594,000 reduced by approximately \$580,000 of formation and operating costs and approximately \$783,000 of income taxes.

### **Liquidity and Capital Resources**

The net proceeds from our initial public offering and the private placement, after deducting offering expenses of approximately \$6,150,000, including underwriting discount (other than the deferred underwriting discount of \$4,050,000), were \$132,835,000. Of this amount, \$132,725,000 (including the \$4,000,000 proceeds of the private placement) was placed in the trust account and the remaining \$125,000 was made available to us to fund our operating expenses. Under the Trust Agreement, up to \$2,125,000 of the interest earned on the trust account (net of taxes) may be used by us to cover a portion of our operating expenses. Through June 30, 2008, approximately \$749,000 of such interest was distributed to us for working capital and another approximately \$1,167,000 was distributed to pay taxes on the Trust interest income. Additionally, approximately \$685,000 is reflected as due to us on our condensed balance sheet at June 30, 2008. During the three months ended June 30, 2008, we incurred approximately \$1,380,000 in costs related to a potential acquisition, approximately \$1,100,000 of which remain unpaid at June 30, 2008.

Prior to the consummation of our initial public offering, our only source of liquidity was an advance made to us on July 16, 2007, by Pecksland Partners, LLC, one of our stockholders and an affiliate of our officers, in the amount of \$210,000, which was used to pay a portion of the expenses of our initial public offering. In addition, during March 2008, Pecksland Partners, LLC, made an advance to us in an amount equal to \$245,000 to provide us with liquidity to cover certain tax expenses. On June 6, 2008, the outstanding principal amount of \$455,000 due Pecksland Partners, LLC as well as \$11,567.93 of interest was paid in full.

### **Off-Balance Sheet Arrangements**

Other than contractual obligations incurred in the normal course of business, we do not have any off-balance sheet financing arrangements or liabilities, guarantee contracts, retained or contingent interests in transferred assets or any obligation arising out of a material variable interest in an unconsolidated entity. We do not have any majority-owned subsidiaries.

### **Critical Accounting Policies and Accounting Estimates**

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the periods reported. Actual results could materially differ from those estimates. We have determined that we currently are not subject to any critical accounting policies.

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk**

Market risk is the sensitivity of income to changes in interest rates, foreign exchanges, commodity prices, equity prices, and other market driven rates or prices. We are not presently engaged in any substantive commercial business. Accordingly, the risks associated with foreign exchange rates, commodity prices, and equity prices are not significant. The net proceeds of our initial public offering held in the trust fund and not immediately required for the purposes set forth above have been invested only in United States government securities within the meaning of Section 2(a)(16) of the Investment Company Act of 1940 having a maturity of one hundred and eighty days or less. Given our limited risk in our exposure to U.S. Treasury Bills, we do not view the interest rate risk to be significant. We do not enter into derivatives or other financial instruments for trading or speculative purposes.

**Table of Contents**

**Item 4. Controls And Procedures**

**Evaluation of Disclosure Controls and Procedures**

We maintain disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Based on their evaluation as of the end of the period covered by this Report, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective in timely alerting them to material information relative to our company required to be disclosed in our periodic filings with the SEC.

**Changes in Internal Control Over Financial Reporting**

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2008, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**Table of Contents**

**PART II OTHER INFORMATION**

**Item 1. Legal Proceedings**

None.

**Item 1A. Risk Factors**

There have been no material changes to the factors disclosed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2007. Please see the information disclosed in the Risk Factors section of our Annual Report filed on Form 10-K, as filed with the SEC on March 31, 2008.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Submission of Matters to a Vote of Security Holders**

None.

**Item 5. Other Information**

None.

**Item 6. Exhibits**

(a) Exhibits

<b>Exhibit #</b>	<b>Description</b>
31.1	Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer of the Company.*
31.2	Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer of the Company.*
32.1	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
32.2	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

\* Filed herewith



**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**GOLDEN POND HEALTHCARE, INC.**

Date: August 12, 2008

*/s/ Stephen F. Wiggins*  
Stephen F. Wiggins, Chairman of the Board and President

Date: August 12, 2008

*/s/ Michael C. Litt*  
Michael C. Litt, Chief Financial Officer and Secretary